Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
Creator
Krammer, Florian
Simon, Viviana
Amanat, Fatima
Nowak, Michael
Arunkumar, Guha
Fabre,
Hernandez, Matthew
Jhang, Jeffrey
Jiang, Kaijun
Mcmahon, Meagan
Sordillo, Emilia
Stadlbauer, Daniel
Tan, Jessica
Teo, Catherine
Shelcie,
Van 6 Bakel, Harm
Source
MedRxiv
abstract
By conducting a retrospective, cross-sectional analysis of SARS-CoV-2 seroprevalence in a sentinel group (enriched for SARS-CoV-2 infections) and a screening group (representative of the general population) using >5,000 plasma samples from patients at Mount Sinai Hospital in New York City (NYC), we identified seropositive samples as early as in the week ending February 23, 2020. A stark increase in seropositivity in the sentinel group started the week ending March 22 and in the screening group in the week ending March 29. By the week ending April 19, the seroprevalence in the screening group reached 19.3%, which is well below the estimated 67% needed to achieve community immunity to SARS-CoV-2. These data potentially suggest an earlier than previously documented introduction of SARS-CoV-2 into the NYC metropolitan area.
has issue date
2020-06-29
(
xsd:dateTime
)
bibo:doi
10.1101/2020.06.28.20142190
has license
medrxiv
sha1sum (hex)
b5d9d83fd761e84dc3efe8d97645b950e486eecf
schema:url
https://doi.org/10.1101/2020.06.28.20142190
resource representing a document's title
Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
resource representing a document's body
covid:b5d9d83fd761e84dc3efe8d97645b950e486eecf#body_text
is
schema:about
of
named entity 'retrospective'
named entity 'Seroconversion'
named entity 'CONDUCTING'
named entity 'seroprevalence'
named entity 'SARS-CoV-2'
named entity 'seroprevalence'
named entity 'Mount Sinai Hospital'
named entity 'preprint'
named entity 'New York State'
named entity 'February 9'
named entity 'standard of care'
named entity 'nucleotide sequences'
named entity 'sensitivity, specificity'
named entity 'week ending'
named entity 'codon'
named entity 'Microsoft'
named entity 'week ending'
named entity 'SARS-CoV-2'
named entity 'seroprevalence'
named entity 'virus'
named entity 'antibody'
named entity 'false positives'
named entity 'Seroprevalence'
named entity 'epidemic'
named entity 'seroprevalence'
named entity 'plasma'
named entity 'SARS-CoV-2'
named entity 'April 5'
named entity 'recombinant'
named entity '1:400'
named entity 'SARS-CoV-2'
named entity 'preprint'
named entity 'serological'
named entity 'April 19'
named entity 'SARS-CoV-2'
named entity 'Institutional Review Board'
named entity 'elective surgeries'
named entity 'MSHS'
named entity 'epidemic'
named entity 'peer review'
named entity 'plasma'
named entity 'emergency department'
named entity 'plasma'
named entity 'GraphPad Prism'
named entity '95% confidence interval'
named entity 'April 2020'
named entity 'serology'
named entity 'oncology'
named entity 'infection rate'
named entity 'Cardiology'
named entity 'monoclonal antibody'
named entity 'medRxiv'
named entity 'human coronaviruses'
named entity 'virus infections'
named entity 'infection'
named entity 'seroprevalence'
named entity 'NPV'
named entity 'medRxiv'
named entity 'recombinant'
named entity 'serosurvey'
named entity 'medRxiv'
named entity 'microtiter plates'
named entity 'Mann-Whitney U test'
named entity 'antibody'
named entity 'o-phenylenediamine'
named entity '1:50'
named entity 'PBS'
named entity 'serially diluted'
named entity 'seroprevalence'
named entity 'preprint'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 4
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software